Physician profile
Jason Ning
NPI 1588149843
$5,251.36
in general payments reported to CMS, 2019-2025
21 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $383 · 2021: $221 · 2022: $151 · 2023: $1,028 · 2024: $1,421 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,057.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,390.30 | 2019-2025 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Abbvie INC. | $1,208.63 | 2023-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $647.38 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Alcon Vision LLC | $555.06 | 2023-2025 | Clareon, Rocklatan |
| Harrow Eye, LLC | $426.48 | 2024-2025 | Vevye, Iheezo |
| Bausch & Lomb Americas INC. | $164.61 | 2022-2025 | Miebo, Xiidra |
| Mallinckrodt Hospital Products INC. | $138.48 | 2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $127.05 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $104.81 | 2019 | |
| Visioneering Technologies, INC. | $95.57 | 2019 | |
| Ivantis, INC | $92.42 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $52.67 | 2025 | Xdemvy |
| Takeda Pharmaceuticals U.S.A., INC. | $47.37 | 2021 | |
| Sun Pharmaceutical Industries INC. | $45.32 | 2021-2024 | |
| Dompe US, INC. | $36.83 | 2025 | Oxervate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $32.16 | 2023 | |
| Omeros Corporation | $19.30 | 2021 | |
| Thea Pharma INC. | $18.66 | 2023 | |
| Oyster Point Pharma, INC. | $18.49 | 2025 | Tyrvaya |
| Ani Pharmaceuticals, INC. | $17.29 | 2025 | Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Ning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.